FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* TOMSICEK MICHAEL JOHN						2. Issuer Name and Ticker or Trading Symbol CRISPR Therapeutics AG [CRSP]									eck all applic Directo Officer	tionship of Reporting all applicable) Director Officer (give title		10% Owner Other (specify	
	,	APEUTICS, IN	(Middle) C.		3. Date of Earliest Transaction (Month/Day/Year) 03/10/2020									below)	below) below) Chief Financial Officer				
(Street) CAMBR (City)			02139 (Zip)		4. If	4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person										ı			
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transa Date (Month/D				Execution Date,		Code (Instr. 5)				Securitie Beneficia	5. Amount of Securities Beneficially Owned Following		: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)					
								Code	v	Amount	(A) or (D) Price		Price	Transact	Transaction(s) (Instr. 3 and 4)			(111341.4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
Derivative Conversion Date Security or Exercise (Month/Day/Year)			3A. Deemed Execution D if any (Month/Day	Date, T	4. Transaction Code (Instr. 8)				6. Date Exercisa Expiration Date (Month/Day/Year		e of Se ar) Unde Deriv		7. Title and Amou of Securities Underlying Derivative Securit (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e S Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				C	Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title	or Nu of	umber					
Stock Option (Right to Buy)	\$44.67	03/10/2020			A		35,000		(1)	0	3/10/2030	Commo Shares	n 35	5,000	\$0.00	35,000)	D	
Restricted Stock Units	(2)	03/10/2020			A		8,500		(3)		(3)	Commo Shares	8	3,500	\$0.00	8,500		D	

Explanation of Responses:

- 1. This option was granted on March 10, 2020 with respect to 35,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 10, 2020.
- 2. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
- 3. This restricted stock unit award was granted on March 10, 2020 with respect to 8,500 Common Shares, with (i) one third of the shares vesting on March 10, 2021, (ii) one third of the shares shares vesting on March 10, 2022, and (iii) one third of the shares vesting on March 10, 2023.

Remarks:

/s/ Michael Esposito, attorney-

03/12/2020

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.